AstraZeneca: FDA OKs Once-Daily Qtern for Type-2 Diabetes
February 28 2017 - 2:49AM
Dow Jones News
By Ian Walker
LONDON--Pharmaceutical giant AstraZeneca PLC (AZN.LN) said
Tuesday the U.S. Food and Drug Administration has approved
once-daily Qtern for the treatment of type-2 diabetes.
The new medicine is indicated as an addition to diet and
exercise to improve blood sugar level control in adults with type-2
diabetes who have inadequate control with dapagliflozin, or who are
already treated with dapagliflozin and saxagliptin, Astra said.
-Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749
(END) Dow Jones Newswires
February 28, 2017 02:34 ET (07:34 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Sep 2023 to Sep 2024